New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
07:38 EDTPETX, ADXSAdvaxis files for USDA product license
Advaxis (ADXS) announced that a product license from the USDA has been filed for ADXS-cHER2, its proprietary Her2/neu-directed cancer immunotherapy for the treatment of canine osteosarcoma and other HER2-overexpressing cancers. The filing was submitted by Aratana Therapeutics (PETX), which was granted exclusive worldwide rights by Advaxis to develop and commercialize ADXS-cHER2 in animals. While the USDA has no specific obligation to respond within a prescribed timeframe, the companies expect a response from the USDA to the filing will occur over the next 12 to 18 months.
News For ADXS;PETX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
18:22 EDTPETXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Red Hat (RHT), up 9.3%... Pier 1 Imports (PIR), up 8%... NQ Mobile (NQ), up 9.3%... Cintas (CTAS), up 6.3%. ALSO HIGHER: Aratana Therapeutics (PETX), up 25.9% after candidate for dog osteoarthritis shows positive results... Ally Financial (ALLY), up 5% after announcing that it will exit the Troubled Asset Relief Program. DOWN AFTER EARNINGS: Nike (NKE), down 2.7%. ALSO LOWER: American Apparel (APP), down 2.8% after New York Post reports on takeover bid.
16:55 EDTPETXAratana Therapeutics' candidate for dog osteoarthritis shows positive results
Aratana Therapeutics announced positive results from its pivotal field study of AT-001 - Grapiprant -, the company's drug for treating pain in dogs with osteoarthritis. In the study, dogs receiving AT-001 demonstrated improvements in pain assessment scores that were statistically significant compared to placebo at a once-daily oral dose. Aratana expects to commence commercialization upon FDA approval, which Aratana anticipates in 2016.
December 16, 2014
16:30 EDTPETXAratana Therapeutics initiates pivotal study for AT-003
Subscribe for More Information
December 15, 2014
07:33 EDTADXSAdvaxis announces FDA acceptance of INDA to commence clinical trials of ADXS-HPV
Subscribe for More Information
December 8, 2014
09:20 EDTADXSOn The Fly: Pre-market Movers
Subscribe for More Information
07:35 EDTADXSAdvaxis reports FDA acceptance of IND application for ADXS-PSA combination trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use